Radiotherapy using the hypoxic cell sensitizer Ro 03-8799 in malignant melanoma.
The hypoxic cell sensitizer Ro 03-8799 has been given with radiotherapy to achieve complete and sustained regression in 5 of 7 cases of recurrent malignant melanoma treated with the object of cure and in 1 of 3 treated palliatively. Particularly high tumour concentrations of this radiosensitizing drug have been found in 3 of 6 cases studied.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D000860:Hypoxia / Q000378:metabolism*; D008198:Lymph Nodes / Q000378:metabolism / Q000473:pathology; D008297:Male; D008545:Melanoma / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy; D009593:Nitroimidazoles / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010166:Palliative Care / Q000379:methods; D011836:Radiation Tolerance; D011838:Radiation-Sensitizing Agents / Q000493:pharmacokinetics*; D012878:Skin Neoplasms / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy*
D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; C033815:pimonidazole